Call Today
Diagnostics
To inquire about our available technologies, call our office (813) 745-6828
| Name & Description | Number |
|---|---|
| Protein Diagnostic: Quantum Dots Conjugated with Antibodies for Early Cancer Detection | 04A064 |
| Protein Signature: Discriminating Common Adenocarcinomas | 05A014 |
| Genetic Signature: Metastatic Melanoma Stage Identification | 06B073 |
| Plasma Protein Biomarker: Diagnosis of Ovarian Cancer | 06B098 |
| Protein Biomarker: Predicting Response to Immunosuppression in MDS | 07A056 |
| Genetic Signature: Predicting Tumor Aggressiveness | 07B108 |
| Protein Biomarker: Diagnostic biomarker for Acute Myeloid Leukemia (AML) M5 Subtype | 07B113 |
| Genetic Signature: Seven-Gene Signature Test for Prediction of Breast Cancer Recurrence | 08A016 |
| Antibody Diagnostic: Monitoring Multiple Myeloma Progression and Recurrence | 08MA005 |
| Genetic Signature: Immune-related Gene Signature to Influence Treatment Decisions and Predict Immunotherapy Outcomes in Cancer | 09MA014 |
| Protein Biomarker/Genetic Signature: Diagnostic for the Classification of Carcinomas of Unknown Primary Site (CUP) | 10MA009 |
| Genetic Signature: Novel Gene Signature for Prediction of Response to Standard of Care for High Grade Gliomas | 10MA013 |
| Molecular Imaging Probe: Breast Cancer-Targeted Probe Set for Improved Detection of Lymph Node Metastases | 10MA024 |
| Molecular Imaging Probe: Fluorescent and MRI Targeted Probes for the Melanocortin Receptor 1 on Melanomas, and Micelle Complexes for Drug Delivery | 10MB069N |
| Genetic Signature: New CREB Gene Signature for Improved Ovarian Cancer Therapy Management | 11MA006 |
| Protein Diagnostic: New Receptor Tyrosine Kinase Assay for Patient Treatment Selection Based on Protein-Protein Bindi | 11MA014 |
| Imaging: Digital Pathology Tool to Grade Breast Cancer Histological Images | 11MA022 |
| Molecular Imaging Probe: Surrogate Markers for Colon Adenoma and Adenocarcinoma | 11MA026N |
| Genetic Signature: Method of Detecting MDS Using hTERT Activity | 11MB061N |
| Molecular Imaging Probe: Synthetic Fluorescent Probe for Improved Detection and Tumor Removal in Pancreatic Cancer Patients | 11MB064 |
| Gene Signature for Immunotherapy Response Prediction in Cancer Based on Nuclear Factor-kappa B | 11MB069 |
| Protein Signature: Method of Diagnosing Chronic Lymphocytic Leukemia | 11MB072N |
| Protein Diagnostic: Mass Spectrometry Diagnostic for BRAF and Heat Shock Proteins | 11MB087N |
| Genetic Signature: Five Gene Signature Predicts Overall and Recurrence-Free Survival in NSCLC | 12MA023N |
| Genetic Signature: Novel Gene Polymorphisms to Predict Prostate Cancer Recurrence and Guide Therapy Options | 12MA045 |
| Genetic Signature: Gene Expression Signature to Determine the Benefit of Adjuvant Chemotherapy in Early Stage Non-Small Cell Lung Cancer | 12MA069 |
| Molecular Imaging Probe: A Novel 18F Scaffold for Preparing Targeted PET Imaging Probess | 12MB104 |
| Protein Diagnostic: Phosphorylated STAT3 Protein as a Novel Biomarker of Graft Versus Host Disease | 13MA002 |
| Multiplex Diagnostic: Detection of Minimal Residual Disease in Multiple Myeloma Using RNA Sequencing and Mass Spectrometry | 13MA009 |
| Genetic Signature: Gene Signature Predicts Recurrence and Benefit From Adjuvant Chemotherapy in Colorectal Cancer | 13MA036 |
| Imaging: Decision Support Tool for Oncology Treatment that Analyzes Radiological Images | 13MB047 |
| Cell Imaging: Apparatus and Method for Selecting Cancer Treatment Regimens for Multiple Myeloma | 13MB048N |
| Molecular Imaging: Texture Feature Analysis of Low-Dose CT Images for Pulmonary Nodule Diagnosis | 13MB054 |
| Molecular Imaging: Novel Imaging Software Diagnostic to Determine Survival in Glioblastoma Multiforme | 13MB055 |
| Molecular Imaging: PET Probes of Radiofluorinated Carboximidamides for IDO-Targeted Imaging | 13MB056N |
| miRNA Diagnostic: Blood Based microRNA Assay to Detect Malignant Intraductal Papillary Mucinous Neoplasms (IPMNs) | 13MB078 |
| miRNA Diagnostic: Signature to Predict Progression of Barrett’s Esophagus to Esophageal Dysplasia or Adenocarcinoma | 13MB080 |
| Protein Biomarker: Expression of WEE1 and PAXIP1 Can Select Patients who Respond to WEE1 Inhibitor Therapys | 14MA001 |
| Gene Signature to Predict Distant Metastasis in Stage I Lung Cancer Patients Treated with Surgery | 14MA008 |
| Genetic Signature: Microarray-based Gene Expression Profiling to Predict Tumor Sensitivity to Radiotherapy | 14MA052N |
| Molecular Imaging: Monoacylated TLR2 Ligand Fluorescent Probe for Detecti | 15MA015 |
| Diagnostic: Intracellular S100A9 Alone or NLRP3 Inflammasome Activation as MDS Biomarkers | 15MA021N |
| Diagnostic: S100A9 Serum Concentration Levels Predict Lenalidomide Response Duration | 15MA031N |
| Molecular Imaging Probe: In vivo Positron Emission Tomography-Based Perfusion/Blood Pool Imaging Using Labeled Erythrocytes | 15MB042N |
| Protein Biomarker: Diagnostic for Progression of MDS to AML Using PD-1 or PD-L1 Expression | 15MB065 |
| Genetic Signature: Gene Signature to Distinguish Lung Squamous Cell Carcinoma from Metastatic Head & Neck Squamous Cell Carcinoma | 16MB040 |
| Protein Biomarker: Method for Measuring MRE11 in Muscle –Invasive Bladder Cancer to Predict Chemoradiation Response Using AQUA | 16MB041 |
| Protein Biomarker: Diagnostic to Determine which Low-Risk MDS Patients to Treat with Lenalidomide to Restore Sensitivity to Erythropoietin | 16MB042 |
| Molecular Imaging Probe: Novel IDO1-Targeting Cancer Diagnostic PET Imaging Agent | 16MB044 |
| miRNA Diagnostic: MicroRNA Signature to Predict Progression of Barrett’s Esophagus to Esophageal Dysplasia or Adenocarcinoma | 16MB066 |
| miRNA Diagnostic: miRNA Signature for Non-invasive Early Detection of Malignancy in IPMN | 17MA001 |
| Molecular Imaging: Predicting Response to Adjuvant Ipilimumab Treatment in Melanoma Using a Novel Algorithm to Analyze Nitric Oxide Levels in Peripheral Blood Immune Cells | 17MA002N |
| Genetic Biomarker: PTEN Loss of Expression as a Biomarker Response to GGTI-2418 Treatment | 17MA025 |
| Genetic Signature: Gene Signature to Distinguish between Metastatic Urothelial Carcinoma and Squamous Cell Carcinoma (Primary Lung and Metastatic Head & Neck) | 17MB044 |
| Mathematical Modeling: Methods for the Treatment of Prostate Cancer Using Intermittent Adaptive Therapy | 18MB055N |
| Mathematical Modeling: Predict Patient-Specific Radiotherapy Responses Using a Proliferation Saturation Index in an Adaptive Bayesian Approach | 18MB083N |
| Mathematical Modeling: Novel algorithm that measures obesity related risks of surgery using segmentation of adiposity on abdominal CT scans | 19MA001N |
